---
title: "Thursday 3/26 Insider Buying Report: RPC, TPST"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280672308.md"
description: "On March 26, insider buying activity was reported for RPC and Tempest Therapeutics (TPST). Director David M. McCoy of Ridgepost Capital bought 70,000 shares of RPC at $7.37 each, totaling $515,900, with RPC shares up 3.1%. Meanwhile, CEO Matthew Angel purchased $500,001 worth of TPST, acquiring 231,482 shares at $2.16 each, while TPST shares fell 4.6%, trading as low as $1.65, 23.8% below Angel's purchase price."
datetime: "2026-03-26T17:55:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280672308.md)
  - [en](https://longbridge.com/en/news/280672308.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280672308.md)
---

# Thursday 3/26 Insider Buying Report: RPC, TPST

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

At Ridgepost Capital, a filing with the SEC revealed that on Monday, Director David M. McCoy purchased 70,000 shares of RPC, at a cost of $7.37 each, for a total investment of $515,900. Ridgepost Capital is trading up about 3.1% on the day Thursday.

And on Tuesday, CEO and President Matthew Angel bought $500,001 worth of Tempest Therapeutics, buying 231,482 shares at a cost of $2.16 each. Tempest Therapeutics is trading down about 4.6% on the day Thursday. Investors can bag TPST at a price even lower than Angel did, with shares trading as low as $1.65 in trading on Thursday which is 23.8% under Angel's purchase price.

**VIDEO: Thursday 3/26 Insider Buying Report: RPC, TPST**

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [RES.US](https://longbridge.com/en/quote/RES.US.md)
- [TPST.US](https://longbridge.com/en/quote/TPST.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Tempest Therapeutics Q1 net loss widens on asset acquisition costs](https://longbridge.com/en/news/286464103.md)
- [AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC](https://longbridge.com/en/news/286750290.md)
- [Vertex Says Health Canada Accepts Suzetrigine Application for Review](https://longbridge.com/en/news/287257602.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)